Tecan stock holds steady as 2025 sales and profit frame the outlook

Tecan Holding AG (ISIN CH0012100191) is framed by full-year 2025 sales of CHF 934.3 million, reported operating profit of CHF 168.6 million, and an EBIT margin of 18.0%. The latest annual figures also include net income of CHF 125.7 million, and the company proposed a dividend of CHF 3.30 per share for 2025.

CHF 934.3 million sales

For 2025, Tecan reported sales of CHF 934.3 million and said that this compared with CHF 977.7 million in 2024, a decline of 4.4%. The same full-year report showed the company still generated CHF 168.6 million in EBIT, equal to an 18.0% margin, which helps explain why the stock remains a closely watched Swiss healthcare technology name.

Net income came in at CHF 125.7 million in 2025, after CHF 138.0 million in 2024, while the board proposed a dividend of CHF 3.30 per share for the year. Those numbers matter because they show a business that remained profitable even as sales eased year on year.

Margin at 18.0%

Tecan also said it continued a share repurchase program of up to CHF 220.0 million. That program gives the market a second balance-sheet and capital-return reference point alongside the dividend, and it is a more concrete signal than broad commentary about confidence.

The comparison is the key detail: sales fell 4.4% year on year, yet the EBIT margin still reached 18.0% in 2025. In a market that tends to reward both resilience and cash discipline, that combination is usually more important than a single headline number.

Sample logistics systems

One representative product line for Tecan is its liquid handling and automation platforms, which sit at the core of the company’s lab workflow portfolio. In practical terms, that product mix matters because the annual report ties the company’s revenue base to instruments and consumables used in life sciences and diagnostics laboratories.

That connection is useful for investors because the 2025 numbers show how the installed base, recurring demand, and margin structure interact. The stock story is therefore less about a single quarter and more about whether Tecan can keep sales, profitability, and capital returns aligned after a softer revenue year.

Swiss healthcare technology

Tecan is traded in Switzerland on SIX Swiss Exchange under the ticker TECN, within the healthcare technology segment. The company’s 2025 report gives the most recent dated reference point in this article: sales of CHF 934.3 million, EBIT of CHF 168.6 million, net income of CHF 125.7 million, and a proposed dividend of CHF 3.30 per share.

As of the latest report reference, the shares should be read against those 2025 figures rather than against a fresh price print.